Form D · Biotechnology
OrthoBio Therapeutics, Inc.
Vail, CO · CIK 0001904099
Offering snapshot reported Jul 2, 2025 · SEC filing
- Reported sold
- $31.4M Offering amount: $31.4M
- Investors reported
- 45 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 23, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 2, 2025 | Initial | $31,449,768 | No comparison | 45 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-550586
Source: Form D, filed Jul 2, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lodewijk De Vink | Director |
| William T. Esrey | Director |
| Jessica Hopfield | Director |
| Robert Hugin | Director |
| Peter J. Millett | Director, Executive |
| Marc Prisant | Executive |
| Stanley Shuman | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1300 N. Frontage Road, #5937
Vail, CO, 81657
Vail, CO, 81657